Xeris Biopharma Holdings Inc (XERS)
2.18
+0.08
(+3.81%)
USD |
NASDAQ |
Jun 26, 14:30
Xeris Biopharma Holdings Enterprise Value: 454.40M for June 25, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 25, 2024 | 454.40M |
| June 24, 2024 | 456.62M |
| June 21, 2024 | 455.14M |
| June 20, 2024 | 452.18M |
| June 18, 2024 | 458.11M |
| June 17, 2024 | 465.52M |
| June 14, 2024 | 468.48M |
| June 13, 2024 | 471.45M |
| June 12, 2024 | 474.41M |
| June 11, 2024 | 483.31M |
| June 10, 2024 | 486.28M |
| June 07, 2024 | 487.76M |
| June 06, 2024 | 492.21M |
| June 05, 2024 | 502.58M |
| June 04, 2024 | 486.28M |
| June 03, 2024 | 505.55M |
| May 31, 2024 | 476.64M |
| May 30, 2024 | 471.45M |
| May 29, 2024 | 428.46M |
| May 28, 2024 | 426.97M |
| May 24, 2024 | 428.46M |
| May 23, 2024 | 431.42M |
| May 22, 2024 | 440.32M |
| May 21, 2024 | 438.83M |
| May 20, 2024 | 446.25M |
| Date | Value |
|---|---|
| May 17, 2024 | 435.87M |
| May 16, 2024 | 441.80M |
| May 15, 2024 | 435.87M |
| May 14, 2024 | 424.01M |
| May 13, 2024 | 422.53M |
| May 10, 2024 | 403.25M |
| May 09, 2024 | 421.04M |
| May 08, 2024 | 416.60M |
| May 07, 2024 | 421.04M |
| May 06, 2024 | 423.27M |
| May 03, 2024 | 422.53M |
| May 02, 2024 | 418.08M |
| May 01, 2024 | 401.77M |
| April 30, 2024 | 401.77M |
| April 29, 2024 | 401.77M |
| April 26, 2024 | 401.77M |
| April 25, 2024 | 394.35M |
| April 24, 2024 | 403.25M |
| April 23, 2024 | 406.21M |
| April 22, 2024 | 406.21M |
| April 19, 2024 | 400.28M |
| April 18, 2024 | 403.25M |
| April 17, 2024 | 406.21M |
| April 16, 2024 | 409.18M |
| April 15, 2024 | 416.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
20.14M
Minimum
Apr 02 2020
565.12M
Maximum
Mar 01 2024
267.34M
Average
243.58M
Median
Mar 14 2023
Enterprise Value Benchmarks
| Amgen Inc | 225.63B |
| Regeneron Pharmaceuticals Inc | 109.54B |
| Kodiak Sciences Inc | -111.96M |
| INmune Bio Inc | 122.90M |
| Phathom Pharmaceuticals Inc | 432.63M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -18.98M |
| Revenue (Quarterly) | 40.64M |
| Total Expenses (Quarterly) | 54.88M |
| EPS Diluted (Quarterly) | -0.14 |
| Gross Profit Margin (Quarterly) | 85.31% |
| Profit Margin (Quarterly) | -46.71% |
| Earnings Yield | -21.10% |
| Normalized Earnings Yield | -21.57 |